[go: up one dir, main page]

CY1113025T1 - 2-μεθυλ-1-(φαινυλσουλφονυλ)-4-(πιπεραζιν-1-υλ)-1η-βενζιμιδαζολη ως προσδεμα 5-υδροξυτρυπταμινης-6 - Google Patents

2-μεθυλ-1-(φαινυλσουλφονυλ)-4-(πιπεραζιν-1-υλ)-1η-βενζιμιδαζολη ως προσδεμα 5-υδροξυτρυπταμινης-6

Info

Publication number
CY1113025T1
CY1113025T1 CY20121100721T CY121100721T CY1113025T1 CY 1113025 T1 CY1113025 T1 CY 1113025T1 CY 20121100721 T CY20121100721 T CY 20121100721T CY 121100721 T CY121100721 T CY 121100721T CY 1113025 T1 CY1113025 T1 CY 1113025T1
Authority
CY
Cyprus
Prior art keywords
piperazin
benzimidazole
hydroxytryptamine
phenylsulfonyl
methyl
Prior art date
Application number
CY20121100721T
Other languages
English (en)
Inventor
Simon N Haydar
Patrick M Andrae
Heedong Yun
Albert J Robichaud
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41404503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113025(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of CY1113025T1 publication Critical patent/CY1113025T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/22—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η εφεύρεση αναφέρεται σε ενώσεις 1-(αρυλσουλφονυλ)-4-(πιπεραζιν-1-υλ)-1Η-βενζιμιδαζόλης Τύπου Ι: ή ένα ταυτομερές, στερεοϊσομερές ή φαρμακευτικά αποδεκτό άλας αυτών, όπου οι συστατικές μεταβλητές είναι όπως ορίζεται στο παρόν, συνθέσεις που περιλαμβάνουν τις ενώσεις και μεθόδους για τη δημιουργία και χρήση των ενώσεων.
CY20121100721T 2008-11-11 2012-08-13 2-μεθυλ-1-(φαινυλσουλφονυλ)-4-(πιπεραζιν-1-υλ)-1η-βενζιμιδαζολη ως προσδεμα 5-υδροξυτρυπταμινης-6 CY1113025T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11329608P 2008-11-11 2008-11-11
EP09752080A EP2285784B1 (en) 2008-11-11 2009-11-10 2-methyl-1-(phenylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazole as 5-hydroxytryptamine-6 ligand

Publications (1)

Publication Number Publication Date
CY1113025T1 true CY1113025T1 (el) 2016-04-13

Family

ID=41404503

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100721T CY1113025T1 (el) 2008-11-11 2012-08-13 2-μεθυλ-1-(φαινυλσουλφονυλ)-4-(πιπεραζιν-1-υλ)-1η-βενζιμιδαζολη ως προσδεμα 5-υδροξυτρυπταμινης-6

Country Status (41)

Country Link
US (1) US8063053B2 (el)
EP (1) EP2285784B1 (el)
JP (1) JP5087171B2 (el)
KR (1) KR101323417B1 (el)
CN (1) CN102209713B (el)
AP (1) AP2814A (el)
AR (1) AR074325A1 (el)
AU (1) AU2009314221B2 (el)
BR (1) BRPI0920682A2 (el)
CA (1) CA2740262C (el)
CL (1) CL2011001050A1 (el)
CO (1) CO6440548A2 (el)
CR (1) CR20110247A (el)
CU (1) CU24020B1 (el)
CY (1) CY1113025T1 (el)
DK (1) DK2285784T3 (el)
DO (1) DOP2011000130A (el)
EA (1) EA018369B1 (el)
EC (1) ECSP11011045A (el)
ES (1) ES2389694T3 (el)
GE (1) GEP20135805B (el)
HR (1) HRP20120561T1 (el)
IL (1) IL212213A0 (el)
MA (1) MA32788B1 (el)
ME (1) ME01129B (el)
MX (1) MX2011004996A (el)
MY (1) MY156324A (el)
NI (1) NI201100093A (el)
NZ (1) NZ592563A (el)
PE (1) PE20120026A1 (el)
PL (1) PL2285784T3 (el)
PT (1) PT2285784E (el)
RS (1) RS52381B (el)
SA (1) SA109300673B1 (el)
SI (1) SI2285784T1 (el)
SV (1) SV2011003902A (el)
TN (1) TN2011000203A1 (el)
TW (1) TWI481605B (el)
UA (1) UA100192C2 (el)
WO (1) WO2010056644A1 (el)
ZA (1) ZA201103283B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005329423A1 (en) * 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CN101084207A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
MX2007003329A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y biciclicos y su uso como inhibidores de estearoil-coa-desaturasa (scd).
US7951805B2 (en) * 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
CN104557726B (zh) * 2013-10-19 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
CA2953004C (en) 2014-07-08 2023-02-21 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
WO2017052394A1 (en) 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
EP3530651A1 (en) * 2018-02-21 2019-08-28 Adamed sp. z o.o. Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists
US12398097B2 (en) 2019-07-29 2025-08-26 Vanderbilt University WDR5-MYC inhibitors
CA3179331A1 (en) * 2020-04-22 2021-10-28 Recurium Ip Holdings, Llc Preparation of an selective estrogen receptor degrader

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2194984C (en) * 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
US5849759A (en) * 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
PL338016A1 (en) 1997-07-11 2000-09-25 Smithkline Beecham Plc Novel chemical compounds
GB9716656D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
SI0930302T1 (en) 1998-01-16 2003-10-31 F. Hoffmann-La Roche Ag Benzosulfone derivatives
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
DE69905171T2 (de) * 1998-08-10 2003-11-20 Dept Of Veterans Affairs Washi Prodrugs für proton-pump-inhibitoren
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
SE0003810D0 (sv) * 2000-10-20 2000-10-20 Pharmacia Ab Novel compounds their use and preparations
NZ524675A (en) 2000-10-20 2004-09-24 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-N1-(benzensulfonyl) indoles and their use in therapy
US7034029B2 (en) * 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
WO2002036562A2 (en) * 2000-11-02 2002-05-10 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
JP2005501019A (ja) * 2001-06-15 2005-01-13 エフ．ホフマン−ラ　ロシュ　アーゲー ５−ｈｔ６レセプター親和性を有する４−ピペラジニルインドール誘導体
WO2003026666A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
JP4768265B2 (ja) 2002-10-15 2011-09-07 シンタ ファーマシューティカルズ コーポレーション 新規化合物
TWI380816B (zh) 2004-04-13 2013-01-01 Synta Pharmaceuticals Corp 抑制介白素-１２（ｉｌ-１２）生成之二鹽抑制劑
JP2008508314A (ja) 2004-07-28 2008-03-21 アイアールエム・リミテッド・ライアビリティ・カンパニー ステロイドホルモン核内受容体のモジュレーターとしての化合物および組成物
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders

Also Published As

Publication number Publication date
CL2011001050A1 (es) 2011-08-19
MY156324A (en) 2016-02-15
CA2740262A1 (en) 2010-05-20
DK2285784T3 (da) 2012-07-23
CR20110247A (es) 2011-06-24
US20100120779A1 (en) 2010-05-13
PT2285784E (pt) 2012-09-19
CA2740262C (en) 2013-05-28
IL212213A0 (en) 2011-06-30
KR20110075013A (ko) 2011-07-05
EP2285784B1 (en) 2012-07-04
ME01129B (me) 2013-03-20
UA100192C2 (en) 2012-11-26
JP2012508275A (ja) 2012-04-05
AP2814A (en) 2013-12-31
PL2285784T3 (pl) 2012-12-31
MA32788B1 (fr) 2011-11-01
DOP2011000130A (es) 2017-04-30
RS52381B (sr) 2012-12-31
AU2009314221B2 (en) 2012-08-30
SI2285784T1 (sl) 2012-08-31
AU2009314221A1 (en) 2010-05-20
AR074325A1 (es) 2011-01-05
EP2285784A1 (en) 2011-02-23
JP5087171B2 (ja) 2012-11-28
GEP20135805B (en) 2013-04-10
TN2011000203A1 (fr) 2012-12-17
EA018369B1 (ru) 2013-07-30
KR101323417B1 (ko) 2013-10-29
NI201100093A (es) 2011-10-31
CU20110101A7 (es) 2012-01-31
CO6440548A2 (es) 2012-05-15
ECSP11011045A (es) 2011-06-30
WO2010056644A8 (en) 2010-11-18
WO2010056644A1 (en) 2010-05-20
AP2011005664A0 (en) 2011-04-30
ES2389694T3 (es) 2012-10-30
MX2011004996A (es) 2011-05-25
BRPI0920682A2 (pt) 2016-09-27
PE20120026A1 (es) 2012-02-12
CN102209713A (zh) 2011-10-05
EA201100696A1 (ru) 2011-10-31
SA109300673B1 (ar) 2013-05-25
SV2011003902A (es) 2011-07-05
US8063053B2 (en) 2011-11-22
NZ592563A (en) 2012-10-26
TW201022247A (en) 2010-06-16
CN102209713B (zh) 2014-07-02
CU24020B1 (es) 2014-07-30
TWI481605B (zh) 2015-04-21
HRP20120561T1 (hr) 2012-07-31
HK1158647A1 (en) 2012-07-20
ZA201103283B (en) 2012-01-25

Similar Documents

Publication Publication Date Title
CY1113025T1 (el) 2-μεθυλ-1-(φαινυλσουλφονυλ)-4-(πιπεραζιν-1-υλ)-1η-βενζιμιδαζολη ως προσδεμα 5-υδροξυτρυπταμινης-6
CY1119530T1 (el) Συνθεσεις και μεθοδοι ρυθμισης toy fxr
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
ECSP12011625A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
CY1119534T1 (el) Παραγωγα φωσφορου ως αναστολεις κινασης
CY1117776T1 (el) Εναντιομερη ενωσεων σπειρο-οξινδολιου και οι χρησεις τους ως θεραπευτικοι παραγοντες
CY1110392T1 (el) Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης
CY1118909T1 (el) Αμιδια οξαλικου οξεος ως αναστολεις νεπριλυσινης, φαρμακευτικη συνθεση αυτων και παρασκευη αυτων
CY1113924T1 (el) Ενωσεις καρβαζολης και θεραπευτικες χρησεις των ενωσεων
CY1116034T1 (el) 2-ανιλινοβενζιμιδαζολο-6-καρβοξαμιδια ως αντι-φλεγμονωδεις παραγοντες
CY1116628T1 (el) Ενωσεις σπειρο-οξινδολιου και χρηση αυτων ως θεραπευτικοι παραγοντες
CY1121677T1 (el) Ενωσεις διμεθυλοβενζοϊκου οξεος
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
CY1116399T1 (el) Πυραζολυλαμινοπυριδινες ως αναστολεις της fak
UY30842A1 (es) Derivados de n-(amino-heteroaril)-1h-pirrolopiridin-2-carboxamidas, su preparacion y su aplicacion en terapéutica
CY1118541T1 (el) D2 αποκλειστες, μεθοδοι συνθεσης και μεθοδοι χρησης
CY1117085T1 (el) C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης
CY1118093T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν παραγωγα 1-(bhta-d-γλυκοπυρανοζυλ)-2-θειενυλμεθυλβενζολιου ως αναστολεις sglt
CY1114354T1 (el) Νεα παραγωγα βενζαμιδιου ως ανταγωνιστες βραδυκινινης
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы
EP2581372A4 (en) CYANOCHINOLINDERIVATE
CY1112366T1 (el) Ενωσεις βενζιμιδαζολης- καρβοξαμιδης ως αγωνιστες του 5-ητ4 υποδοχεα
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
CY1115729T1 (el) Τρικυκλικη ενωση και φαρμακευτικη χρηση αυτης
CY1114020T1 (el) 3-αμινοκυκλοπεντανοκαρβοξαμιδια ως διαμορφωτες υποδοχεα χημοκινης